eHealth2030

Your health in your hands

Our Work

We are dedicated to innovation in drug discovery and digital health. 

We provide strategic guidance, governance, management leadership and seed capital.

Govern

  • Leads or participates in the developments of new companies, including EG427 and Atiaspharma
  • Role : Executive Chairman / CEO / Board Member

current boards

EG427
Gene therapy start up, with a licensed technology and a completed seed round

Chairman, CEO and founder

nova
Accelerating drug development with virtual trial design and tools

Chairman

atias
Transformative therapies for endocrine diseases

Founder, vice chairman

Selected past board memberships

Acquired by Endo, 2015
Acquired by Endo, 2015
Acquired by AthenaHealth, 2013
Acquired by AthenaHealth, 2013
Acquired by Quest Diagnostics, 2006
Acquired by Quest Diagnostics, 2006
Acquired by Roivant Sciences, 2017
Acquired by Roivant Sciences, 2017
Acquired by Frenesius, 2017
Acquired by Frenesius, 2017
Acquired by Tripos, 2008
Acquired by Tripos, 2008
Acquired by Evicore Healthcare, 2016
Acquired by Evicore Healthcare, 2016
Acquired by Optum/United Healthcare, 2014
Acquired by Optum/United Healthcare, 2014
Acquired by WebMD
Acquired by WebMD
Acquired by Tibco, 2007
Acquired by Tibco, 2007
Truveris
FEETME
tribun

Invest

  • Either directly in private companies or via partnerships

current investments include

Leads the field of on demand enzyme based DNA synthesis
Gene therapy start up, with a licensed technology and a complete seed round
Leads the field of off the shelf Gamma Delta T cell therapy for cancers
Develops, manufactures and sell Tyto, a device enabling remote consultation based on the real time collection and sharing of relevant vital metrics
Develops a proprietary formulation of the leading multiple sclerosis treatment agent
Accelerates the development of next-generation genetic tests by providing biologists with tools for high-resolution genetic analysis

Philippe Chambon

Managing Director

Contact Philippe

Over the years, Philippe Chambon has gained a wealth of experience in healthcare. Indeed, he co-founded EG427, a leader in gene therapy for Peripheral Nervous System diseases, and chairs Novadiscovery, driving healthcare innovation. Philippe also co-founded Atias Pharmaceuticals and served as a Venture Partner at LBO France, a leading French private equity firm with a dedicated focus on digital health ventures. He has also either founded, invested in, managed or advised numerous other companies in this sector (New Leaf Venture Partners, The Sprout Group and others).

His educational background includes an MBA from Columbia University, an MD PhD from Université Paris Descartes, and a DEA in Microbiology from Institut Pasteur. Philippe’s career exemplifies his commitment to build the future of healthcare through innovation and strategic leadership.

Linkedin Mail-bulk
Close Menu
en_GBEnglish (UK)
fr_FRFrançais en_GBEnglish (UK)